|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 2S. Anti-Ebola GP IgG ELISA Titers from Experiment 1** | | | | | | | | | | | | |
| Group | Animal ID | GP IgG ELISA (EU/mL) by study day | | | | | | | | | | |
| -7 | 3 | 6 | 7 | 8 | 9 | 10 | 12 | 14 | 21 | 28 |
| Saline control | 1 | <LOQ | <LOQ | <LOQ | NT | <LOQ | NT | NT | NT | NT | NT | NT |
| 2 | <LOQ | <LOQ | <LOQ | <LOQ | NT | NT | NT | NT | NT | NT | NT |
| EI: Irrelevant Tc hIgG control | 3 | <LOQ | <LOQ | <LOQ | <LOQ | NT | NT | NT | NT | NT | NT | NT |
| 4 | <LOQ | <LOQ | <LOQ | NT | <LOQ | NT | NT | NT | NT | NT | NT |
| 5 | <LOQ | <LOQ | <LOQ | <LOQ | NT | NT | NT | NT | NT | NT | NT |
| 6 | <LOQ | <LOQ | <LOQ | NT | <LOQ | NT | NT | NT | NT | NT | NT |
| 7 | <LOQ | <LOQ | <LOQ | NT | <LOQ | NT | NT | NT | NT | NT | NT |
| 8 | <LOQ | <LOQ | <LOQ | NT | NT | NT | NT | NT | NT | NT | NT |
| EI: SAB-139/ V3-V4 | 9 | <LOQ | 4,606 | 660 | NT | 1,188 | NT | NT | NT | NT | NT | NT |
| 10 | <LOQ | 2,908 | 1,644 | NT | NT | 530 | NT | NT | NT | NT | NT |
| 11 | <LOQ | 7,042 | 7,425 | NT | NT | NT | 1,014 | <LOQ | NT | NT | NT |
| 12 | <LOQ | 6,221 | 4,634 | NT | NT | NT | 805 | 1,279 | NT | NT | NT |
| 13 | <LOQ | 6,190 | 5,104 | NT | NT | NT | 1,171 | 1,788 | 2,899 | 5,799 | >LOQ |
| 14 | <LOQ | 6,011 | 6,319 | NT | NT | NT | 2,511 | 3,332 | 7,554 | 4,557 | 3,200 |

Abbreviations: EI, early intervention (treatment initiated d 1 postexposure); EU, ELISA units; GP, glycoprotein; ID: identification number; LOQ, limit of quantification; NT, not tested; Tc hIgG, transchromosomic human Immunoglobulin G.